Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Launch pad damaged as Russian rocket blasts off for space station, agency says - 2Dental Embed Innovation: An Achievement in Helpful Dentistry
- 3Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- 4Minneapolis ICE shooting live updates: Protests continue over agent's killing of Renee Nicole Good; Walz puts National Guard on standby
- 5Manual for 6 Busssiness Class Flights
- Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- Monetary Wellness: Planning Tips for Independence from the rat race
- Really focusing on Succulents: Tips and Procedures
- Instructions to Pick the Best Course for Your Next Waterway Voyage: Objections, Views, and Social Encounters
- Philippines evacuates 3,000 villagers after volcano activity raises alert level
- Congo declares its latest Ebola outbreak over, after 43 deaths
- An Investigate of 6 Creative Specialty Mixed drinks
- Simple Consideration Plants for Home and Office: An Aide
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
